| Heading: |
Trastuzumab Deruxtecan |
| Question ID: |
1761338 |
| UIN: |
28293 |
| House: |
Commons |
| Date tabled: |
2025-02-03 |
| Asking Member ID: |
5283 |
| Asking Member display name: |
Alison Bennett
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Alison Bennett
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, if he will make a comparative assessment of levels of access to Enhertu for cancer patients in (a) England, (b) Wales, (c) Northern Ireland and (d) Scotland. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-02-11 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
No assessment has been made, as health is a devolved matter and decisions on the availability of medicines in Scotland, Wales, and Northern Ireland are a matter for their own administrations.Decisions on whether new medicines should be routinely funded by... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |